JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Doximity (NYSE:DOCS) Stock

Doximity (NYSE:DOCS) had its price target boosted by stock analysts at JPMorgan Chase & Co. from $26.00 to $31.00 in a report released on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 9.42% from the stock’s previous close.

Several other equities analysts also recently issued reports on the company. Canaccord Genuity Group set a $36.00 price objective on Doximity in a research report on Friday. BMO Capital Markets restated a “market perform” rating and set a $30.00 target price on shares of Doximity in a report on Friday. Barclays restated an “equal weight” rating and set a $20.00 target price (down from $38.00) on shares of Doximity in a report on Thursday, May 14th. Bank of America restated an “underperform” rating and issued a $20.00 target price (down from $38.00) on shares of Doximity in a research note on Monday, June 29th. Finally, KeyCorp cut Doximity from an “overweight” rating to a “sector weight” rating in a report on Thursday, May 14th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $31.19.

Doximity Stock Performance

Shares of NYSE DOCS traded up $7.67 during mid-day trading on Friday, hitting $28.33. 39,370,051 shares of the stock were exchanged, compared to its average volume of 4,013,574. The company has a market cap of $5.18 billion, a P/E ratio of 28.46, a PEG ratio of 7.85 and a beta of 1.29. The stock’s fifty day simple moving average is $21.16 and its two-hundred day simple moving average is $24.35. Doximity has a twelve month low of $17.15 and a twelve month high of $76.51.

Doximity (NYSE:DOCS) last announced its earnings results on Thursday, August 6th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.16 by $0.13. The business had revenue of $156.62 million for the quarter. Doximity had a return on equity of 20.40% and a net margin of 30.40%.The firm’s revenue was up 7.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.36 earnings per share. As a group, equities research analysts predict that Doximity will post 0.87 earnings per share for the current fiscal year.

Insider Activity at Doximity

In related news, insider Siddharth Sitaram sold 2,444 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $20.41, for a total value of $49,882.04. Following the completion of the sale, the insider owned 90,706 shares in the company, valued at approximately $1,851,309.46. This represents a 2.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 31.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Doximity

Several institutional investors have recently modified their holdings of DOCS. Vanguard Group Inc. boosted its stake in Doximity by 4.1% during the 4th quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock worth $588,281,000 after acquiring an additional 518,916 shares during the last quarter. UBS Group AG increased its stake in Doximity by 26.5% in the fourth quarter. UBS Group AG now owns 680,260 shares of the company’s stock valued at $30,122,000 after purchasing an additional 142,408 shares in the last quarter. Carmignac Gestion raised its holdings in Doximity by 127.8% in the first quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock worth $100,480,000 after purchasing an additional 2,418,971 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of Doximity by 325,436.6% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,298,891 shares of the company’s stock worth $57,515,000 after purchasing an additional 1,298,492 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB boosted its position in shares of Doximity by 174.1% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 372,750 shares of the company’s stock worth $16,505,000 after purchasing an additional 236,750 shares in the last quarter. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Revenue beat and stronger full-year outlook: Doximity reported quarterly revenue of $156.6 million, up 7.3% year over year, and raised fiscal 2027 revenue guidance to $671 million–$681 million, slightly above Wall Street’s prior estimate. Doximity Shares Soar After Revenue Beat and Higher Full-Year Forecast
• Positive Sentiment: AI is the main catalyst: Management said its clinical AI search product generated approximately 10 times the revenue required to operate it, while the CEO said the company’s clinical AI performance exceeded Anthropic in internal comparisons. Investors view AI-driven engagement and future monetization as potential upside not fully reflected in current guidance. Shares of this digital medical platform were up more than 100% at one point
• Positive Sentiment: Analyst sentiment improved: Analysts raised price targets and became more constructive on Doximity’s growth prospects following the results and AI commentary, adding momentum to the stock. DOCS stock soars after CEO says clinical AI outperformed Anthropic
• Neutral Sentiment: Trading volatility was extreme: Multiple limit-up/limit-down pauses were reported as trading volume surged, indicating unusually high speculative activity and heightened short-term volatility. LinkedIn for Doctors Stock Nearly Doubles After Earnings
• Negative Sentiment: Earnings were mixed: Adjusted EPS of $0.29 exceeded some published consensus estimates but fell short of the $0.30 Zacks estimate and declined from $0.36 a year earlier. Second-quarter revenue guidance of $170 million–$171 million was also marginally below the consensus estimate of $171.1 million. Doximity Q1 Earnings Lag Estimates

Doximity Company Profile

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.